(VTR) Ventas - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US92276F1003
Senior Housing, Medical Buildings, Research Centers, Healthcare Facilities
Dividends
| Dividend Yield | 2.34% |
| Yield on Cost 5y | 4.58% |
| Yield CAGR 5y | -4.27% |
| Payout Consistency | 97.1% |
| Payout Ratio | 3.8% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 17.9% |
| Value at Risk 5%th | 27.9% |
| Relative Tail Risk | -5.34% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.23 |
| Alpha | 25.14 |
| CAGR/Max DD | 1.12 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.296 |
| Beta | 0.271 |
| Beta Downside | 0.400 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.88% |
| Mean DD | 7.28% |
| Median DD | 6.00% |
Description: VTR Ventas October 14, 2025
Ventas, Inc. (NYSE: VTR) is a S&P 500-listed REIT focused on health-care real estate, operating roughly 1,400 properties across North America and the United Kingdom. Its core assets are more than 850 senior-housing communities, complemented by outpatient medical buildings, research centers, and other health-care facilities, positioning the company within the expanding “longevity economy.”
Key operational metrics show a FY 2023 occupancy rate of ~94% across senior-housing assets and a FY 2023 Funds-From-Operations (FFO) growth of 5% year-over-year, supporting a current dividend yield of about 5.5%. The portfolio’s performance is closely tied to macro drivers such as the U.S. aging demographic (projected to add ~10 million adults aged 65+ by 2030) and the prevailing interest-rate environment, which influences REIT cap rates and borrowing costs.
For investors seeking deeper quantitative insight, exploring ValueRay’s proprietary analytics on Ventas’ cash-flow sensitivity to interest-rate shifts can reveal hidden upside or downside scenarios worth further investigation.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (238.0m TTM) > 0 and > 6% of Revenue (6% = 333.3m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA 1.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -8.89% (prev 6.51%; Δ -15.40pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 1.55b > Net Income 238.0m (YES >=105%, WARN >=100%) |
| Net Debt (12.60b) to EBITDA (2.15b) ratio: 5.87 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.63 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (456.4m) change vs 12m ago 8.80% (target <= -2.0% for YES) |
| Gross Margin 41.97% (prev 42.61%; Δ -0.64pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 21.25% (prev 18.94%; Δ 2.31pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.07 (EBITDA TTM 2.15b / Interest Expense TTM 752.5m) >= 6 (WARN >= 3) |
Altman Z'' -1.87
| (A) -0.02 = (Total Current Assets 849.3m - Total Current Liabilities 1.34b) / Total Assets 26.93b |
| (B) -0.27 = Retained Earnings (Balance) -7.37b / Total Assets 26.93b |
| (C) 0.03 = EBIT TTM 808.6m / Avg Total Assets 26.14b |
| (D) -1.01 = Book Value of Equity -14.66b / Total Liabilities 14.50b |
| Total Rating: -1.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 60.75
| 1. Piotroski 3.0pt |
| 2. FCF Yield 2.31% |
| 3. FCF Margin 20.74% |
| 4. Debt/Equity 1.03 |
| 5. Debt/Ebitda 5.87 |
| 6. ROIC - WACC (= -2.24)% |
| 7. RoE 2.06% |
| 8. Rev. Trend 97.51% |
| 9. EPS Trend 44.65% |
What is the price of VTR shares?
As of December 06, 2025, the stock is trading at USD 80.61 with a total of 1,590,609 shares traded.
Over the past week, the price has changed by -0.02%, over one month by +7.51%, over three months by +19.53% and over the past year by +33.61%.
Over the past week, the price has changed by -0.02%, over one month by +7.51%, over three months by +19.53% and over the past year by +33.61%.
Is VTR a buy, sell or hold?
Ventas has received a consensus analysts rating of 4.45.
Therefore, it is recommended to buy VTR.
- Strong Buy: 12
- Buy: 5
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the VTR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 81.9 | 1.5% |
| Analysts Target Price | 81.9 | 1.5% |
| ValueRay Target Price | 94.9 | 17.7% |
VTR Fundamental Data Overview November 25, 2025
Market Cap USD = 37.22b (37.22b USD * 1.0 USD.USD)
P/E Trailing = 149.5095
P/E Forward = 135.1351
P/S = 6.7138
P/B = 3.011
P/EG = 1.7374
Beta = 0.802
Revenue TTM = 5.56b USD
EBIT TTM = 808.6m USD
EBITDA TTM = 2.15b USD
Long Term Debt = 12.57b USD (from longTermDebt, last quarter)
Short Term Debt = 107.3m USD (from shortTermDebt, last quarter)
Debt = 12.79b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.60b USD (from netDebt column, last quarter)
Enterprise Value = 49.82b USD (37.22b + Debt 12.79b - CCE 188.6m)
Interest Coverage Ratio = 1.07 (Ebit TTM 808.6m / Interest Expense TTM 752.5m)
FCF Yield = 2.31% (FCF TTM 1.15b / Enterprise Value 49.82b)
FCF Margin = 20.74% (FCF TTM 1.15b / Revenue TTM 5.56b)
Net Margin = 4.28% (Net Income TTM 238.0m / Revenue TTM 5.56b)
Gross Margin = 41.97% ((Revenue TTM 5.56b - Cost of Revenue TTM 3.22b) / Revenue TTM)
Gross Margin QoQ = 41.58% (prev 41.80%)
Tobins Q-Ratio = 1.85 (Enterprise Value 49.82b / Total Assets 26.93b)
Interest Expense / Debt = 2.34% (Interest Expense 299.7m / Debt 12.79b)
Taxrate = -10.17% (negative due to tax credits) (-6.34m / 62.4m)
NOPAT = 890.9m (EBIT 808.6m * (1 - -10.17%)) [negative tax rate / tax credits]
Current Ratio = 0.63 (Total Current Assets 849.3m / Total Current Liabilities 1.34b)
Debt / Equity = 1.03 (Debt 12.79b / totalStockholderEquity, last quarter 12.36b)
Debt / EBITDA = 5.87 (Net Debt 12.60b / EBITDA 2.15b)
Debt / FCF = 10.93 (Net Debt 12.60b / FCF TTM 1.15b)
Total Stockholder Equity = 11.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.88% (Net Income 238.0m / Total Assets 26.93b)
RoE = 2.06% (Net Income TTM 238.0m / Total Stockholder Equity 11.53b)
RoCE = 3.35% (EBIT 808.6m / Capital Employed (Equity 11.53b + L.T.Debt 12.57b))
RoIC = 3.64% (NOPAT 890.9m / Invested Capital 24.50b)
WACC = 5.88% (E(37.22b)/V(50.01b) * Re(7.01%) + D(12.79b)/V(50.01b) * Rd(2.34%) * (1-Tc(-0.10)))
Discount Rate = 7.01% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 5.90%
[DCF Debug] Terminal Value 79.93% ; FCFE base≈1.00b ; Y1≈1.13b ; Y5≈1.52b
Fair Price DCF = 56.25 (DCF Value 26.42b / Shares Outstanding 469.7m; 5y FCF grow 14.74% → 3.0% )
EPS Correlation: 44.65 | EPS CAGR: 28.66% | SUE: 0.15 | # QB: 0
Revenue Correlation: 97.51 | Revenue CAGR: 10.54% | SUE: 3.72 | # QB: 5
EPS next Quarter (2026-03-31): EPS=0.10 | Chg30d=+0.003 | Revisions Net=-4 | Analysts=5
EPS next Year (2026-12-31): EPS=0.56 | Chg30d=-0.095 | Revisions Net=-2 | Growth EPS=+109.3% | Growth Revenue=+12.6%
P/E Trailing = 149.5095
P/E Forward = 135.1351
P/S = 6.7138
P/B = 3.011
P/EG = 1.7374
Beta = 0.802
Revenue TTM = 5.56b USD
EBIT TTM = 808.6m USD
EBITDA TTM = 2.15b USD
Long Term Debt = 12.57b USD (from longTermDebt, last quarter)
Short Term Debt = 107.3m USD (from shortTermDebt, last quarter)
Debt = 12.79b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.60b USD (from netDebt column, last quarter)
Enterprise Value = 49.82b USD (37.22b + Debt 12.79b - CCE 188.6m)
Interest Coverage Ratio = 1.07 (Ebit TTM 808.6m / Interest Expense TTM 752.5m)
FCF Yield = 2.31% (FCF TTM 1.15b / Enterprise Value 49.82b)
FCF Margin = 20.74% (FCF TTM 1.15b / Revenue TTM 5.56b)
Net Margin = 4.28% (Net Income TTM 238.0m / Revenue TTM 5.56b)
Gross Margin = 41.97% ((Revenue TTM 5.56b - Cost of Revenue TTM 3.22b) / Revenue TTM)
Gross Margin QoQ = 41.58% (prev 41.80%)
Tobins Q-Ratio = 1.85 (Enterprise Value 49.82b / Total Assets 26.93b)
Interest Expense / Debt = 2.34% (Interest Expense 299.7m / Debt 12.79b)
Taxrate = -10.17% (negative due to tax credits) (-6.34m / 62.4m)
NOPAT = 890.9m (EBIT 808.6m * (1 - -10.17%)) [negative tax rate / tax credits]
Current Ratio = 0.63 (Total Current Assets 849.3m / Total Current Liabilities 1.34b)
Debt / Equity = 1.03 (Debt 12.79b / totalStockholderEquity, last quarter 12.36b)
Debt / EBITDA = 5.87 (Net Debt 12.60b / EBITDA 2.15b)
Debt / FCF = 10.93 (Net Debt 12.60b / FCF TTM 1.15b)
Total Stockholder Equity = 11.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.88% (Net Income 238.0m / Total Assets 26.93b)
RoE = 2.06% (Net Income TTM 238.0m / Total Stockholder Equity 11.53b)
RoCE = 3.35% (EBIT 808.6m / Capital Employed (Equity 11.53b + L.T.Debt 12.57b))
RoIC = 3.64% (NOPAT 890.9m / Invested Capital 24.50b)
WACC = 5.88% (E(37.22b)/V(50.01b) * Re(7.01%) + D(12.79b)/V(50.01b) * Rd(2.34%) * (1-Tc(-0.10)))
Discount Rate = 7.01% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 5.90%
[DCF Debug] Terminal Value 79.93% ; FCFE base≈1.00b ; Y1≈1.13b ; Y5≈1.52b
Fair Price DCF = 56.25 (DCF Value 26.42b / Shares Outstanding 469.7m; 5y FCF grow 14.74% → 3.0% )
EPS Correlation: 44.65 | EPS CAGR: 28.66% | SUE: 0.15 | # QB: 0
Revenue Correlation: 97.51 | Revenue CAGR: 10.54% | SUE: 3.72 | # QB: 5
EPS next Quarter (2026-03-31): EPS=0.10 | Chg30d=+0.003 | Revisions Net=-4 | Analysts=5
EPS next Year (2026-12-31): EPS=0.56 | Chg30d=-0.095 | Revisions Net=-2 | Growth EPS=+109.3% | Growth Revenue=+12.6%
Additional Sources for VTR Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle